2024-516347-41-00招募中2 期
PAXIS: A randomized, double-blind, placebo-controlled dose-finding phase 2 study (Part 1) followed by an open-label period (Part 2) to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Sobi Inc.
- 入组人数
- 36
- 试验地点
- 18
- 主要终点
- 1. The primary endpoint is Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period.
研究概览
简要总结
To evaluate the efficacy of two dose levels of pacritinib compared to placebo during the double-blind treatment period in subjects with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of signing the informed consent form (ICF).
- •Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 30 days prior to enrollment and a negative urine pregnancy test on Day 1 prior to randomization and dosing.
- •WOCBP and male subjects must agree to use a highly effective method of contraception starting at the first dose of trial therapy through 30 days after the last dose of trial therapy
- •QT corrected by the Fridericia method (QTcF) ≤ 450 msec in males or ≤ 470 msec in females. Subjects with QRS prolongation >100 msec may enroll if their QTcF is ≤ 480 msec. If QTcF is thought to be prolonged due to a modifiable factor (e.g., medication / electrolyte abnormality), QTcF may be re‑evaluated.
- •Willingness and ability of the subject to comply with protocol requirements, including but not limited to: completing in-person trial visits, completing training in the use of the Prednisone / Prednisolone Dose Diary and recording daily prednisone / prednisolone use in the diary, undergoing trial-related procedures, and completing patient-reported outcome (PRO) assessments.
- •Provision of signed informed consent
- •Documented evidence of a pathogenic or likely pathogenic mutation at methionine-41 (M41) or neighboring splice site mutation (c.118-1, c.118-2) position in UBA1 based on myeloid NGS, droplet digital polymerase chain reaction (ddPCR), or Sanger sequencing in peripheral blood or bone marrow samples.
- •Current or documented evidence of past inflammatory involvement within 6 months prior to enrollment of at least one of the following organ systems by VEXAS syndrome: cutaneous (e.g., neutrophilic dermatosis, cutaneous vasculitis), vasculature (e.g., vasculitis), musculoskeletal (e.g., chondritis, arthritis), ocular (e.g., uveitis, scleritis), periorbital (e.g., periorbital edema), genitourinary (e.g., epididymitis), or pulmonary (e.g., alveolitis). Note: Other inflammatory signs may be considered for enrollment at the discretion of the Investigator with Medical Monitor approval provided that these signs have been previously demonstrated to be GCresponsive (i.e., resolve after administration of or escalation in GC therapy).
- •Receiving ongoing GC therapy (with prednisone or prednisolone) for ≥4 consecutive weeks leading up to enrollment for the treatment of VEXAS syndrome
- •Prednisone or prednisolone baseline dose of 15-45 mg/day that has been stable for ≥10 days prior to enrollment. Note that subjects who are stable on GC doses of 10-14 mg daily in addition to another non-GC anti-inflammatory therapy at Screening who have a previously documented VEXAS flare on GC monotherapy at a dose of ≥10 mg may be eligible provided that their GC dose is escalated to 15-45 mg daily after washout, and that this dose is stable for ≥10 days prior to enrollment.
- •Karnofsky Performance Status ≥50%
- •Adequate organ function, meeting all the following criteria within 30 days prior to (CrCl) ≥30 mL/min based on the Cockcroft-Gault formula; d. Absolute neutrophil count ≥500/μL; e. Prothrombin time (PT) or international normalized raenrollment: a. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN); b. Total bilirubin ≤4 × ULN (≤8 × ULN in the setting of Gilbert’s syndrome); c. Creatinine clearancetio (INR) ≤1.5 × ULN (unless prolonged due to therapeutic anticoagulation); f. Partial thromboplastic time (PTT) or activated PTT ≤1.5 × ULN (unless prolonged due to therapeutic anticoagulation); g. Platelet count ≥25 × 10^9/L (value must be obtained in the absence of platelet transfusion in the prior 7 days); h. Peripheral blasts <5%
排除标准
- •Prior allogenic hematopoietic stem cell transplant (allo-HSCT) or solid organ transplant (other than corneal).
- •Known concomitant multiple myeloma, or serum M-protein ≥3 g/dL, involved-to-uninvolved free light chain (FLC) ratio ≥100, or involved FLC level ≥100 mg/L. Subjects with MGUS may enroll.
- •Systemic treatment with a strong CYP3A4 inhibitor or inducer within 5 half-lives prior to enrollment
- •Significant recent bleeding history defined as National Cancer Institute CTCAE Grade ≥2 within 3 months prior to enrollment, unless precipitated by an inciting event (e.g., surgery or trauma).
- •History of clinically significant cardiovascular disease, including: a.Severe cardiac event (CTCAE Grade ≥3) within 3 months prior to enrollment b.Heart failure resulting in limitations during ordinary activity.
- •Arterial or venous thrombotic or embolic events, including deep vein thrombosis, pulmonary embolism, and cerebrovascular accident (including transient ischemic attacks), within 60 days prior to enrollment.
- •Any condition known to significantly interfere with absorption, distribution, metabolism, or excretion of oral drugs in the opinion of the Investigator.
- •Moderate or severe hepatic impairment that meets criteria for Child-Pugh Class B or C , or active viral hepatitis, including: a) Active hepatitis B virus (HBV) infection: subjects with positive hepatitis B surface antigen (HBsAg) are excluded. Subjects with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Subjects who are hepatitis B PCR positive will be excluded. b) Active hepatitis C virus (HCV) infection: subjects who are positive for HCV antibody are eligible if PCR is negative for HCV RNA. PCR testing is only required if HCV antibody testing is positive.
- •Uncontrolled human immunodeficiency virus (HIV) off antiretrovirals, or on antiretrovirals with detectable viral load. Note: Subjects with a known history of HIV must have viral load assessed for eligibility and must be on a stable antiretroviral regimen that can be administered concurrent with pacritinib.
- •Positive Quantiferon (or other interferon gamma release assay) during Screening. Note: subjects with indeterminant Quantiferon results may enroll.
- •Known history of disseminated mycobacterial infection.
- •Current use of systemic GCs for conditions other than VEXAS syndrome, which, in the opinion of the Investigator, would interfere with adherence to a GC taper regimen and/or assessment of efficacy.
- •Concurrent enrollment in another interventional trial, or treatment with an experimental therapy within 28 days or five half-lives prior to enrollment, whichever is longer.
- •Pregnant, intending to become pregnant during the trial, or currently breastfeeding/lactating.
- •Any unstable disease, intercurrent illness, abnormality, or event (i.e., psychiatric episode, adverse social situation) that could compromise subject safety or affect the conduct of the trial, in the judgment of the treating physician.
- •Subjects with any acute, active infection requiring systemic antimicrobial treatment at the time of enrollment. Exceptions are made for prophylactic antibiotics or chronic antibiotic therapy for non-acute conditions.
- •Known hypersensitivity to pacritinib or any of the following inactive ingredients: microcrystalline cellulose, polyethylene glycol, and magnesium stearate.
- •Persons committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- •More than one prior admission to an intensive care unit due to a VEXAS Syndrome flare within the prior 6 months
- •Received ≥9 units of RBC transfusion in the 90 days prior to enrollment
- •Known concurrent myelodysplastic syndrome (MDS) requiring antineoplastic treatment (e.g., HMAs), or allo-HSCT, or known high-risk or very high-risk MDS based on the Revised International Prognostic Scoring System (IPSS-R). Subjects with MDS who do not meet these criteria may enroll
- •Malignancy within 1 year prior to enrollment with the exception of MDS (per exclusion criterion), curatively treated non-melanoma skin cancer, or curatively treated carcinoma in situ. Subjects with pre-malignant hematologic conditions (e.g., monoclonal gammopathy of unknown significance [MGUS], clonal cytopenia of unknown significance) may enroll.
- •Exposure to HMAs (e.g., azacitidine, decitabine) within 6 months prior to enrollment, or exposure to more than 6 cycles of HMAs at any time.
- •Exposure to the following agents within the following timeframe prior to enrollment a.Anti-CD20 agents (e.g., rituximab): 180 days b.Anti-IL-23 agents (e.g., ustekinumab): 90 days c.Anti-TNFα agents except for etanercept (e.g., infliximab): 60 days d.Canakinumab: 60 days e.Intravenous anti-IL-6 agents: 42 days f.Subcutaneous anti-IL-6 agents: 28 days g.Anti-IL-17 agents (e.g., secukinumab): 28 days h.Anti-integrins (e.g., vedolizumab): 60 days i.Intravenous immunoglobulin: 28 days j.Danazol, immunomodulatory imide drugs (IMiDs), luspatercept, or thrombopoietin receptor agonists: 28 days k.Cytotoxic chemotherapy: 28 days l.Etanercept: 21 days m.Oral JAK inhibitors: 14 days n.Anti-IL-1 agents except for canakinumab: 14 days o.Any other non-GC anti-inflammatory therapy (e.g., mycophenolate, azathioprine, cyclosporine, sulfasalazine, methotrexate): 14 days or 5 half lives, whichever is longer. Note: Subjects on erythropoiesis stimulating agents (ESAs) at the time of informed consent may continue to receive ESAs during Screening and on trial, but new ESA use is not permitted during this 28-day period or on trial.
- •Exposure to anti-platelet therapy with the exception of low-dose aspirin (≤100 mg daily) within 28 days prior to enrollment.
结局指标
主要结局
1. The primary endpoint is Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period.
1. The primary endpoint is Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period.
次要结局
- 1. Best Response (Clinical Biochemical Response, Clinical Response, Partial Clinical Response, Stable Disease, or Non-response) during the double-blind treatment period. Note that Stringent Clinical Biochemical Response is not applicable during the double-blind treatment period (i.e., by Week 24) based on the fixed GC taper schedule
- 2. Number of flare-free days with GC dose <10 mg during the double-blind treatment period.
- 3. Hematologic Improvement – Erythroid (HI-E) at any time during the double-blind treatment period among subjects with baseline hemoglobin <10 g/dL, per modified International Working Group (IWG) criteria.
- 4. Hematologic Improvement – Platelets (HI-P) at any time during the double-blind treatment period among subjects with baseline platelet count <100 × 10^9/L, per modified IWG criteria.
- 5. Change in health-related QOL as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) short forms (fatigue, physical function, sleep disturbance), 36-Item Short Form Health Survey (SF-36), and the Patient Global Impression of Change (PGIC).
- 6. PK of pacritinib.
- 7. PD inflammatory biomarkers (CRP, erythrocyte sedimentation rate [ESR], ferritin)
- 8. Safety and tolerability, assessed by adverse events (AEs), laboratory tests, electrocardiogram (ECG) results, and vital signs will be assessed throughout the double-blind and open-label treatment periods.
研究者
Medical Information
Scientific
Sobi Inc.
研究点 (18)
Loading locations...
相似试验
招募中
2 期
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714Mabwell (Shanghai) Bioscience Co., Ltd.360
招募中
3 期
Efficacy and Safety of Deucravacitinib Compared with Placebo in
Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic
Disease-modifying Anti-rheumatic Drugs2023-506256-25-00Bristol Myers Squibb International Corporation326
招募中
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT07284459Contineum Therapeutics324
进行中（未招募）
3 期
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisNCT07291284Longbio Pharma546
招募中
1 期
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)Focal Cortical DysplasiaNCT07287202Sovargen12